Triptolide suppresses paraquat induced idiopathic pulmonary fibrosis by inhibiting TGFB1-dependent epithelial mesenchymal transition

Hong Chen,Qun Chen,Chun-Ming Jiang,Guang-Yue Shi,Bo-Wen Sui,Wei Zhang,Li-Zhen Yang,Zhu-Ying Li,Li Liu,Yu-Ming Su,Wen-Cheng Zhao,Hong-Qiang Sun,Zhen-Zi Li,Zhou Fu
DOI: https://doi.org/10.1016/j.toxlet.2017.11.030
2018-03-01
Abstract:Idiopathic pulmonary fibrosis (IPF) and tumor are highly similar to abnormal cell proliferation that damages the body. This malignant cell evolution in a stressful environment closely resembles that of epithelial-mesenchymal transition (EMT). As a popular EMT-inducing factor, TGFβ plays an important role in the progression of multiple diseases. However, the drugs that target TGFB1 are limited. In this study, we found that triptolide (TPL), a Chinese medicine extract, exerts an anti-lung fibrosis effect by inhibiting the EMT of lung epithelial cells. In addition, triptolide directly binds to TGFβ and subsequently increase E-cadherin expression and decrease vimentin expression. In in vivo studies, TPL improves the survival state and inhibits lung fibrosis in mice. In summary, this study revealed the potential therapeutic effect of paraquat induced TPL in lung fibrosis by regulating TGFβ-dependent EMT progression.
What problem does this paper attempt to address?